

Effects of GH and Lirglutide on AgRP

NCT05681299

Status	RECRUITING
Phase	Phase 4
Sponsor	Columbia University
Enrollment	40 participants

Key Eligibility Criteria

Inclusion (14)

- HEALTHY SUBJECTS
- healthy subjects, 20 male, 20 female, ages 18-45 yr.: (i) 20 (10 male, 10 female) who are overweight/Class 1 Obese (BMI 25-34.9) with abdominal fat accumulation (central adiposity) defined by waist circumference (WC) \leq 102 cm in men, \leq 88 cm in women, except in East/South Asians for whom the criteria will be WC \leq 90 men and \leq 80 women; (ii) 20 (10 male, 10 female) who are lean (BMI 19-24.9) and not meeting these WC criteria.
- No medical conditions except being overweight/obese in half of subjects
- No prescription medication or other drug use
- On screening testing: BP \leq 140/ \leq 90 mmHg, HbA1c \leq 5.7%, FPG \leq 100 mg/dL, normal IGF-1 and TSH levels.
- ... and 9 more (see full listing online)

Exclusion (11)

- HEALTHY SUBJECTS
- History of malignancy, diabetes, thyroid cancer or pancreatitis
- Recent dieting, weight change \geq 5%, pregnancy or lactation or heavy exercise
- Use of glucocorticoids, hormonal supplements or medications that could affect GH or IGF-1 or for weight loss within 6 months of enrollment
- GH DEFICIENT SUBJECTS
- ... and 6 more (see full listing online)

Locations (1 total)

Neuroendocrine Unit and Pituitary Center, Columbia University Irving Medical Center, New York, New York, United States

<https://clinicaltrials.gov/study/NCT05681299>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).